Abstract:Abstract: Non-alcoholic fatty liver disease (NAFLD) is currently the utmost common chronic liver disorder that happens through all age groups and is identified to occur in 14%-30% of the general population, demonstrating a critical and grossing clinical issue because of the growing incidence of obesity and overweight. From the histological aspect, it looks like alcoholic liver damage, but it happens in patients who avoid remarkable alcohol usage. NAFLD comprises a broad spectrum, ranging from benign hepatocellular steatosis to inflammatory nonalcoholic steatohepatitis (NASH), different levels of fibrosis, and cirrhosis. Patients with NASH are more susceptible to more rapid progression to cirrhosis and hepatocellular carcinoma. There is no single factor that drives proceeding from simple steatosis to NASH. However, a combination of multi parameters such as genetic background, gut microflora, intake of high fat/ fructose dietary contents or methionine/choline-deficient diet, and consequently accumulated hepatocellular lipids mainly including triglycerides and also other bio-analytes, such as free fatty acids, cholesterol, and phospholipids display a crucial role in disease promotion. NAFLD is related to overweight and insulin resistance (IR) and is regarded as the hepatic presentation of the metabolic syndrome, an amalgamation of medical statuses such as hyperlipidemia, hypertension, type 2 diabetes, and visceral obesity. Despite the increasing prevalence of this disease, which imposes a remarkable clinical burden, most affected patients remain undiagnosed in a timely manner, largely related to the asymptomatic entity of NAFLD patients and the unavailability of accurate and efficient noninvasive diagnostic tests. However, liver biopsy is considered a gold standard for NAFLD diagnosis, but due to being expensive and invasiveness is inappropriate for periodic disease screening. Some noninvasive monitoring approaches have been established recently for NAFLD assessment. In addition to the problem of correct disease course prediction, no effective therapeutic modalities are approved for disease treatment. Imaging techniques can commonly validate the screening and discrimination of NAFLD; nevertheless, staging the disease needs a liver biopsy. The present therapeutic approaches depend on weight loss, sports activities, and dietary modifications, although different insulin-sensitizing drugs, antioxidants, and therapeutic agents seem hopeful. This review aims to focus on the current knowledge concerning epidemiology, pathogenesis, and different biochemical experiments and imaging modalities applied to diagnose the different grades of NAFLD and its management, as well as new data about pharmacological therapies for this disorder.

The Study of Hypertension among Patients with Non-Alcoholic Fatty Liver Disease (NAFLD)

[Relationship Between Nonalcoholic Fatty Liver Disease and Cardiovascular Disease in Children with Obesity].

Hypertension and NAFLD Risk: Insights from the NHANES 2017-2018 and Mendelian Randomization Analyses.

NON-ALCOHOLIC FATTY LIVER DISEASE AND HYPERTENSION: CLINICAL VARIABILITY OF COMORBIDITY

Study on the Relationship between Phospholipids and Nonalcoholic Fatty Liver Disease

Hypertension is prevalent in non-alcoholic fatty liver disease and increases all-cause and cardiovascular mortality

A STUDY OF NON ALCOHOLIC FATTY LIVER DISEASE PATIENTS WITH METABOLIC SYNDROME

The Epidemiology, Risk Profiling and Diagnostic Challenges of Nonalcoholic Fatty Liver Disease

Non‐Alcoholic Fatty Liver Disease

Nonalcoholic Fatty Liver Disease: An Emerging Driver of Hypertension

Blood pressure is associated with the presence and severity of nonalcoholic fatty liver disease across the spectrum of cardiometabolic risk

Association Between Hypertension and Nonalcoholic Fatty Liver Disease: a Cross-Sectional and Meta-Analysis Study.

Correlation between Steatosis Degree and Hypertension Degree in Non-Alcoholic Fatty Liver Disease Patients in Indonesia

Nonalcoholic fatty liver disease and risk of incident hypertension: a systematic review and meta-analysis

Recent progresses on pathophysiology, diagnosis, therapeutic modalities, and management of Non-alcoholic fatty liver disorder

Nonalcoholic steatohepatitis: global impact and clinical consequences

Research Progress on Non-Alcoholic Fatty Liver Disease

INFLUENCE OF LIVER FIBROSIS ON LIPID METABOLISM IN PATIENTS WITH ARTERIAL HYPERTENSION AND NON-ALCOHOLIC FATTY LIVER DISEASE

Bidirectional Association between Hypertension and NAFLD: A Systematic Review and Meta-Analysis of Observational Studies

Investigation of cardiovascular risk factors in diabetic and nondiabetic patients with nonalcoholic fatty liver disease

Fatty Liver Disease in Patients with Prediabetes and Overweight or Obesity